搜索结果
靶点ID:TCMBANKGE000119
靶点别名:ACRDYS2; DPDE3; HSPDE4D; PDE43; PDE4DN2; STRK1
靶点描述:phosphodiesterase 4D
染色体:5
染色体位置:5q11.2-q12.1
靶点类型:protein-coding
HERB_ID:HBTAR002905
HGNC_Link:8783
OMIM_Link:600129
Ensembl_Link:ENSG00000113448
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN003665 | evoden | C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O | |||
| TCMBANKIN004707 | phosphatidic acid | C35H69O8P | 648.9 g/mol | CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCCCCCCCCCC | |
| TCMBANKIN031363 | dimethyl sulfoxide | C2H6OS | 78.14 g/mol | CS(=O)C | |
| TCMBANKIN033161 | 1-[(1R,2R,3R,4R)-2,3-dimethyl-4-(2,4,5-trimethoxyphenyl)cyclobutyl]-2,4,5-trimethoxybenzene | 1-[(1R,2R,3R,4R)-2,3-dimethyl-4-(2,4,5-trimethoxyphenyl)cyclobutyl]-2,4,5-trimethoxy-benzene | 416.56 | ||
| TCMBANKIN044790 | oxypeucedanine | oxypeucedanine | C16H18O4 | 274.31 g/mol | COC1CCC2C(C1)OC=C(C2=O)OC3=CC=CC=C3 |
| TCMBANKIN046636 | sophoflavescenol | 216450-65-6; CHEMBL77651; SCHEMBL14563970; LMPK12112538; MolPort-039-339-033; AK685650; 3,7-Dihydroxy-2-(4-hydroxy-phenyl)-5-methoxy-8-(3-methyl-but-2-enyl)-chromen-4-one; CS-6033; ZINC4199939; BDBM50116711; 3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-4H-chromen-4-one; HY-N2284; D00QCL; SOPHOFLAVESCENOL; AKOS032945037 | C21H20O6 | 368.4 g/mol | CC(=CCC1=C2C(=C(C=C1O)OC)C(=O)C(=C(O2)C3=CC=C(C=C3)O)O)C |
| TCMBANKIN059084 | Byakangelicin | (R)-9-(2,3-Dihydroxy-3-methylbutoxy)-4-methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-[(2S)-2,3-dihydroxy-3-methylbutoxy]-4-methoxyfuro[3,2-g]chromen-7-one; 9-[(2R)-2,3-dihydroxy-3-methylbutoxy]-4-methoxy-7-furo[3,2-g]chromenone; 9-[(2R)-2,3-dihydroxy-3-methylbutoxy]-4-methoxyfuro[3,2-g]chromen-7-one; C09141; 7H-Furo(3,2-g)(1)benzopyran-7-one, 9-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-, (R)-; 9-(2,3-Dihydroxy-3-methylbutoxy)-4-methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; Byak-angelicin; Bjacangelicin; MLS000574875; Bjakangelicin; PKRPFNXROFUNDE-NSHDSACASA-N; SMR000156212; Biacangelicin; 7H-FURO(3,2-g)(1)BENZOPYRAN-7-ONE, 9-(2,3-DIHYDROXY-3-METHYLBUTOXY)-4-METHOXY-,; 9-[(2R)-2,3-dihydroxy-3-methyl-butoxy]-4-methoxy-furo[3,2-g]chromen-7-one; ZINC13380829; 482-25-7; AC1NST7W; Byankagelicine; (+)-Byakangelicin; byakangelicin; 9-(2,3-dihydroxy-2-methylbutoxy)-4-methoxy-7H-furo[3,2-g][l]benzopyran-7-one; byak-angelicin | C17H18O7 | 334.3 g/mol | CC(C)(C(COC1=C2C(=C(C3=C1OC(=O)C=C3)OC)C=CO2)O)O |
| TCMBANKIN061371 | nicotine | 36733_RIEDEL; 2yk1; CHEBI:59806; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine; (2S)-1-methyl-2-(pyridin-3-yl)pyrrolidinium; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; D03365; 54-11-5; NCGC00090693-03; 46343_RIEDEL; C00745; Nicotine; NCGC00090693-04; AIDS-156031; 65-31-6 (R,R-BITARTRATE); (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; Habitrol (TN); SBB012359; N5511_SIGMA; (−)-Nicotine; Nicotine (compounds related to); PDSP2_000555; NCT; N3876_SIGMA; 3-[(2S)-1-methyl-2-pyrrolidinyl]pyridine; NCGC00090693-01; ZB012057; (S)-(-)-nicotine; CHEBI:17688; SDCCGMLS-0066911.P001; (S)-nicotinium(1+); AC1OCG5J; 3-(2-(N-methylpyrrolidinyl))pyridine; NSC97238 (R,R-BITARTRATE SALT); 3-[(2S)-1-methylpyrrolidin-1-ium-2-yl]pyridine; (S)-nicotinium cation; AIDS156031; NCGC00090693-05; PDSP1_000465; PDSP1_000113; PDSP2_000463; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; Nicotine (USP); 54-11-5 (FREE BASE); L(-)-nicotine; (−)-Nicotine solution | C10H14N2 | 162.23 g/mol | CN1CCCC1C2=CN=CC=C2 |
| TCMBANKIN061441 | fraxin | ZINC4544768; AC1OIBSZ; 7-hydroxy-6-methoxycoumarin 8-glucoside; 7-hydroxy-6-methoxy-8-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one | C16H18O10 | 370.31 g/mol | COC1=C(C(=C2C(=C1)C=CC(=O)O2)OC3C(C(C(C(O3)CO)O)O)O)O |
| TCMBANKIN061511 | arctigenin | AIDS002466; C10545; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxy-phenyl)methyl]tetrahydrofuran-2-one; arctigenin ; Arctigenin; 41328-87-4; MLS002473154; NCGC00025291-01; MEGxp0_001799; HMS2198I14; Arctigenin, (+)-; (3S,4S)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; 695QU32V04; SMR001397246; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-(3,4-dimethoxybenzyl)-3-(4-hydroxy-3-methoxy-benzyl)tetrahydrofuran-2-one; 7770-78-7; 26687-78-5; (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2(3H)-furanone; AIDS-002466; ACon1_000416; Tocris-1777; (−)-Arctigenin; DTXSID50233381; UNII-2FD8L150E7 component NQWVSMVXKMHKTF-CVEARBPZSA-N; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R-trans)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2-tetrahydrofuranone; (-)-Arctigenin; UNII-695QU32V04; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3S-trans)-; A1854_SIGMA; Arctigenen; 84413-77-4; Arctigenin, trans-(+)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxy-phenyl)methyl]oxolan-2-one; (+)-Arctigenin; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3S,4S)-; ZINC899931; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R,4R)-; CHEMBL369142; (-)-arctigenin | C21H24O6 | 372.4 g/mol | COC1=C(C=C(C=C1)CC2COC(=O)C2CC3=CC(=C(C=C3)O)OC)OC |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000061 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI000066 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI000328 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Nervous System Diseases; Mental Disorders; Behavior and Behavior Mechanisms | - | Disease or Syndrome | disease | |
| TCMBANKDI000439 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI002460 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI002572 | - | - | Finding | disease | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003585 | - | Abnormality of the endocrine system | Finding | phenotype | |
| TCMBANKDI003879 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Male Urogenital Diseases; Endocrine System Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
| TCMBANKDI004145 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI004191 | Chemically-Induced Disorders; Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI006900 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI007110 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
| TCMBANKDI007501 | - | Abnormality of the integument | Finding | phenotype | |
| TCMBANKDI007678 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI008368 | Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI009216 | Behavior and Behavior Mechanisms | - | Mental Process | phenotype | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI009572 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | phenotype | |
| TCMBANKDI009702 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | phenotype | |
| TCMBANKDI009844 | Pathological Conditions, Signs and Symptoms | - | Pathologic Function | phenotype | |
| TCMBANKDI009943 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI011234 | Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011402 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI011883 | - | - | Mental Process | phenotype | |
| TCMBANKDI012157 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | group | |
| TCMBANKDI012677 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI013253 | Pathological Conditions, Signs and Symptoms | Abnormality of the endocrine system | Finding | phenotype | |
| TCMBANKDI013541 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI016890 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI018353 | Chemically-Induced Disorders; Mental Disorders | - | Sign or Symptom | phenotype | |
| TCMBANKDI018716 | Chemically-Induced Disorders; Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI019879 | Digestive System Diseases; Neoplasms; Endocrine System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024559 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI026626 | - | Abnormality of the endocrine system | Finding | phenotype | |
| TCMBANKDI027324 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI028305 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI029520 | Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI029962 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI031570 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease |
滇IICP备16009434号-1 |
Dai SX Lab